



Rec'd PCT/PTO 24 NOV 2003  
4050.001200.ST25  
SEQUENCE LISTING

#10

SMYTHE, MARK LESLIE  
MEUTERMANS, WIM DENIS FRANS  
BOURNE, GREGORY THOMAS  
MCGEARY, ROSS PETER

<120> SYNTHESIS OF CYCLIC PEPTIDES

<130> 4050.001200

<140> 09/806,036

<141> 2001-07-05

<150> PCT/AU99/00813

<151> 1999-09-24

<150> AU PP 6164

<151> 1998-09-25

<160> 76

<170> PatentIn version 3.2

<210> 1

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa = CAT-Arg

<400> 1

Asp Gly Xaa Gly

1

<210> 2

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 2

Xaa Xaa Arg Phe  
1

<210> 3

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 3

Tyr Arg Phe Gly  
1

<210> 4

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 4

Xaa Arg Phe Gly  
1

<210> 5

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 5

Xaa Arg Phe Gly  
1

<210> 6

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 6

Gly Gly Gly Gly

1

<210> 7

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa = Sarcosine

<400> 7

Gly Gly Gly Xaa

1

<210> 8

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa = Sarcosine

<400> 8

Gly Gly Xaa Gly

1

<210> 9

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa = Sarcosine

<400> 9

Gly Xaa Gly Gly  
1

<210> 10

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (3)..(4)

<223> Xaa = Sarcosine

<400> 10

Gly Gly Xaa Xaa  
1

<210> 11

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa = Sarcosine

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa = Sarcosine

<400> 11

Gly Xaa Gly Xaa  
1

<210> 12

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE  
 <222> (2)..(3)  
 <223> Xaa = Sarcosine

<400> 12

Gly Xaa Xaa Gly  
 1

<210> 13  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (2)..(4)  
 <223> Xaa = Sarcosine

<400> 13

Gly Xaa Xaa Xaa  
 1

<210> 14  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = Asp substituted with OBU

<400> 14

Xaa Val Gly Leu  
 1

<210> 15  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = Asp substituted with OBU

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = 2-hydroxy-4-methoxybenzyl-val

<400> 15

Xaa Xaa Gly Leu  
1

<210> 16  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = Asp substituted with OBU

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = 2-hydroxy-4-methoxybenzyl-Gly

<400> 16

Xaa Val Xaa Leu  
1

<210> 17  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 17

Ala Phe Leu Pro Ala  
1 5

<210> 18  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 18

Ala Phe Leu Pro Ala  
1 5

<210> 19  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 19

Xaa Leu Pro Ala Ala  
1 5

<210> 20  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<400> 20

Phe Leu Pro Ala Ala  
1 5

<210> 21  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>SSCH<sub>2</sub>CH<sub>2</sub>-Gly

<400> 21

Xaa Arg Pro Phe Gly  
1 5

<210> 22  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = HSCH2CH2-Gly

<400> 22

Xaa Arg Phe Gly  
1

<210> 23  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = SCH2CH2-Gly

<400> 23

Xaa Arg Pro Phe Gly  
1 5

<210> 24  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = HSCH2CH2-Gly

<400> 24

Xaa Arg Pro Phe Gly  
1 5

<210> 25  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>



<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = Gly substituted with CH<sub>2</sub>CH<sub>2</sub>SH

<400> 25

Xaa Arg Pro Phe Gly  
1 5

<210> 26  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(5-nitro-2-hydroxybenzyl)-Ala

<400> 26

Xaa Phe Leu Pro Ala  
1 5

<210> 27  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Ala

<400> 27

Xaa Phe Leu Pro Ala  
1 5

<210> 28  
<211> 5  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(6-nitro-2-hydroxybenzyl)-Phe

<400> 28

Xaa Leu Pro Ala Ala  
1 5

<210> 29

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 29

Tyr Ala Phe Gly  
1

<210> 30

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 30

Phe Leu Pro Ala Ala  
1 5

<210> 31

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<400> 31

Xaa Arg Phe Gly  
1

<210> 32

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 32

Tyr Xaa Phe Gly  
1

<210> 33  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 33

Tyr Arg Xaa Gly  
1

<210> 34  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 34

Xaa Xaa Phe Gly  
1

<210> 35  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 35

Xaa Arg Xaa Gly

1

<210> 36

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 36

Xaa Xaa Phe Gly

1

<210> 37

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

&lt;400&gt; 37

Xaa Arg Xaa Gly  
1

&lt;210&gt; 38

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; SYNTHETIC LINEAR PEPTIDE

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (2)..(2)

&lt;223&gt; Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

&lt;400&gt; 38

Xaa Xaa Arg Phe  
1

&lt;210&gt; 39

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; SYNTHEHTIC LINEAR PEPTIDE

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (1)..(1)

&lt;223&gt; Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (3)..(3)

&lt;223&gt; Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

&lt;400&gt; 39

Xaa Tyr Xaa Phe  
1

&lt;210&gt; 40

&lt;211&gt; 4

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; SYNTHEHTIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Gly

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 40

Xaa Tyr Arg Xaa  
 1

<210> 41  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC CYCLIC PEPTIDE

<400> 41

Gly Tyr Arg Phe  
 1

<210> 42  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC CYCLIC PEPTIDE

<400> 42

Tyr Arg Phe Ala  
 1

<210> 43  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>  
 <221> MISC\_FEATURE  
 <222> (3)..(3)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 43

Xaa Arg Xaa Ala

1

<210> 44

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<400> 44

Xaa Arg Xaa Ala

1

<210> 45

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Ala

<220>

<221> MISC\_FEATURE

<222> (3)..(3)

<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 45

Xaa Tyr Xaa Phe

1

<210> 46

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (1)..(1)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Tyr

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Arg

<400> 46

Xaa Xaa Phe Gly  
1

<210> 47  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 47

Tyr Arg Phe Gly  
1

<210> 48  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<400> 48

Gly Tyr Arg Phe  
1

<210> 49  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC LINEAR PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = CAT-Arg

<400> 49



Asp Gly Xaa Gly  
1

<210> 50  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = Amb-Arg

<400> 50

Asp Gly Xaa Gly  
1

<210> 51  
<211> 4  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (2)..(2)  
<223> Xaa = Amb-Gly

<400> 51

Asp Xaa Arg Gly  
1

<210> 52  
<211> 8  
<212> PRT  
<213> ARTIFICIAL

<220>  
<223> SYNTHETIC CYCLIC PEPTIDE

<220>  
<221> MISC\_FEATURE  
<222> (3)..(3)  
<223> Xaa = Amb-Arg

<220>  
<221> MISC\_FEATURE  
<222> (7)..(7)  
<223> Xaa = Amb-Arg

<400> 52

Asp Gly Xaa Gly Asp Gly Xaa Gly  
1 5

<210> 53

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa = Me-Phe

<400> 53

Ala Xaa Leu Pro Ala  
1 5

<210> 54

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (2)..(2)

<223> Xaa = Phe substituted with Me

<400> 54

Ala Xaa Leu Pro Ala  
1 5

<210> 55

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = a ring contraction auxiliary comprising O or S linked to Tyr

<220>

<221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa = Gly linked to an activated or safety catch linker linked to resin

<400> 55

Xaa Arg Phe Xaa

1

<210> 56  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = a ring contraction auxiliary comprising O or S linked to Arg

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa = Tyr linked to an activated or safety catch linker linked to resin

<400> 56

Xaa Phe Gly Xaa

1

<210> 57  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = a ring contraction auxiliary comprising O or S linked to Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa = Arg linked to an activated or safety catch linker linked to resin

<400> 57

Xaa Gly Tyr Xaa

1

<210> 58  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = a ring contraction auxiliary comprising O or S linked to  
 Gly

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa = Phe linked to an activated or safety catch linker linked to  
 resin

<400> 58

Xaa Tyr Arg Xaa  
 1

<210> 59  
 <211> 7  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 59

Pro Phe Asn Ser Leu Ala Ile  
 1 5

<210> 60  
 <211> 7  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<400> 60

Asn Ser Leu Ala Ile Pro Phe  
 1 5

<210> 61  
 <211> 4  
 <212> PRT  
 <213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 61

Phe Phe Phe Phe  
1

<210> 62

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (5)..(5)

<223> Xaa = Beta-Ala

<400> 62

Phe Trp Lys Gly Xaa  
1 5

<210> 63

<211> 7

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 63

Pro Phe Asn Ser Leu Ala Ile  
1 5

<210> 64

<211> 14

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 64

Asn Ser Leu Ala Ile Pro Phe Asn Ser Leu Ala Ile Pro Phe  
1 5 10

<210> 65

<211> 21

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

&lt;400&gt; 65

Asn Ser Leu Ala Ile Pro Phe Asn Ser Leu Ala Ile Pro Phe Asn Ser  
 1 5 10 15

Leu Ala Ile Pro Phe  
 20

&lt;210&gt; 66

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; SYNTHETIC CYCLIC PEPTIDE

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (5)..(5)

&lt;223&gt; Xaa = Beta-Ala

&lt;400&gt; 66

Leu Asp Val Gly Xaa  
 1 5

&lt;210&gt; 67

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; SYNTHETIC CYCLIC PEPTIDE

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (5)..(5)

&lt;223&gt; Xaa = Beta-Ala

&lt;400&gt; 67

Arg Gly Asp Gly Xaa  
 1 5

&lt;210&gt; 68

&lt;211&gt; 5

&lt;212&gt; PRT

&lt;213&gt; ARTIFICIAL

&lt;220&gt;

&lt;223&gt; SYNTHETIC CYCLIC PEPTIDE

&lt;220&gt;

&lt;221&gt; MISC\_FEATURE

&lt;222&gt; (5)..(5)

<223> Xaa = Beta-Ala

<400> 68

Phe Lys Trp Gly Xaa  
1 5

<210> 69

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa = substituted Pro

<400> 69

Ala Phe Leu Xaa  
1

<210> 70

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 70

Tyr Arg Phe Gly  
1

<210> 71

<211> 7

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<400> 71

Tyr Ala Phe Gly Tyr Pro Ser  
1 5

<210> 72

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE

<400> 72

Ala Pro Leu Phe Ala  
1 5

<210> 73

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa = Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester  
appended to resin

<400> 73

Ala Phe Leu Xaa  
1

<210> 74

<211> 4

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC LINEAR PEPTIDE

<220>

<221> MISC\_FEATURE

<222> (1)..(1)

<223> Xaa = N-(2-hydroxy-4-nitrobenzyl)-Ala

<220>

<221> MISC\_FEATURE

<222> (4)..(4)

<223> Xaa = Pro-[N-(4-(5-oxyvaleric acid)benzyl)]-L-Alanine allyl ester  
linked to resin

<400> 74

Xaa Phe Leu Xaa  
1

<210> 75

<211> 5

<212> PRT

<213> ARTIFICIAL

<220>

<223> SYNTHETIC CYCLIC PEPTIDE



<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = N-(2-hydroxy-4-nitrobenzyl)-Ala  
 <400> 75

Xaa Phe Leu Pro Ala  
 1 5

<210> 76  
 <211> 5  
 <212> PRT  
 <213> ARTIFICIAL

<220>  
 <223> SYNTHETIC LINEAR PEPTIDE

<220>  
 <221> MISC\_FEATURE  
 <222> (1)..(1)  
 <223> Xaa = a ring contraction auxiliary containing O or S linked to  
 Ala

<220>  
 <221> MISC\_FEATURE  
 <222> (2)..(2)  
 <223> Xaa = N-(2-hydroxy-6-nitrobenzyl)-Phe

<220>  
 <221> MISC\_FEATURE  
 <222> (4)..(4)  
 <223> Xaa = Pro-Backbone linker and resin

<400> 76

Xaa Xaa Leu Xaa Ala  
 1 5